Novo Nordisk says Ozempic 2 mg cuts major cardiovascular event risk vs Mounjaro
Novo Nordisk said real-world analysis at EASD found Ozempic (semaglutide) 2 mg was linked to a 6% lower risk of major cardiovascular events versus switching to Mounjaro (tirzepatide).